410 related articles for article (PubMed ID: 33535988)
21. A radiomics nomogram based on multiparametric MRI might stratify glioblastoma patients according to survival.
Zhang X; Lu H; Tian Q; Feng N; Yin L; Xu X; Du P; Liu Y
Eur Radiol; 2019 Oct; 29(10):5528-5538. PubMed ID: 30847586
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of a multi-modality fusion deep learning model for differentiating glioblastoma from solitary brain metastases.
Shen S; Li C; Fan Y; Lu S; Yan Z; Liu H; Zhou H; Zhang Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Jan; 49(1):58-67. PubMed ID: 38615167
[TBL] [Abstract][Full Text] [Related]
23. Differentiation of recurrent glioblastoma from radiation necrosis using diffusion radiomics with machine learning model development and external validation.
Park YW; Choi D; Park JE; Ahn SS; Kim H; Chang JH; Kim SH; Kim HS; Lee SK
Sci Rep; 2021 Feb; 11(1):2913. PubMed ID: 33536499
[TBL] [Abstract][Full Text] [Related]
24. Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
Barajas RF; Hamilton BE; Schwartz D; McConnell HL; Pettersson DR; Horvath A; Szidonya L; Varallyay CG; Firkins J; Jaboin JJ; Kubicky CD; Raslan AM; Dogan A; Cetas JS; Ciporen J; Han SJ; Ambady P; Muldoon LL; Woltjer R; Rooney WD; Neuwelt EA
Neuro Oncol; 2019 Mar; 21(4):517-526. PubMed ID: 30277536
[TBL] [Abstract][Full Text] [Related]
25. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
26. The effect of glioblastoma heterogeneity on survival stratification: a multimodal MR imaging texture analysis.
Liu Y; Zhang X; Feng N; Yin L; He Y; Xu X; Lu H
Acta Radiol; 2018 Oct; 59(10):1239-1246. PubMed ID: 29430935
[TBL] [Abstract][Full Text] [Related]
27. Differentiation of progressive disease from pseudoprogression using MRI histogram analysis in patients with treated glioblastoma.
Yildirim M; Baykara M
Acta Neurol Belg; 2022 Apr; 122(2):363-368. PubMed ID: 33555560
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
29. Prediction of Pseudoprogression versus Progression using Machine Learning Algorithm in Glioblastoma.
Jang BS; Jeon SH; Kim IH; Kim IA
Sci Rep; 2018 Aug; 8(1):12516. PubMed ID: 30131513
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
[TBL] [Abstract][Full Text] [Related]
31. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 - Radiological features and metric markers.
Le Fèvre C; Constans JM; Chambrelant I; Antoni D; Bund C; Leroy-Freschini B; Schott R; Cebula H; Noël G
Crit Rev Oncol Hematol; 2021 Mar; 159():103230. PubMed ID: 33515701
[TBL] [Abstract][Full Text] [Related]
32. Machine Learning-based Texture Analysis of Contrast-enhanced MR Imaging to Differentiate between Glioblastoma and Primary Central Nervous System Lymphoma.
Kunimatsu A; Kunimatsu N; Yasaka K; Akai H; Kamiya K; Watadani T; Mori H; Abe O
Magn Reson Med Sci; 2019 Jan; 18(1):44-52. PubMed ID: 29769456
[TBL] [Abstract][Full Text] [Related]
33. Radiomics in peritumoral non-enhancing regions: fractional anisotropy and cerebral blood volume improve prediction of local progression and overall survival in patients with glioblastoma.
Kim JY; Yoon MJ; Park JE; Choi EJ; Lee J; Kim HS
Neuroradiology; 2019 Nov; 61(11):1261-1272. PubMed ID: 31289886
[TBL] [Abstract][Full Text] [Related]
34. MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy.
Horvat N; Veeraraghavan H; Khan M; Blazic I; Zheng J; Capanu M; Sala E; Garcia-Aguilar J; Gollub MJ; Petkovska I
Radiology; 2018 Jun; 287(3):833-843. PubMed ID: 29514017
[TBL] [Abstract][Full Text] [Related]
35. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
36. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH
Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475
[TBL] [Abstract][Full Text] [Related]
37. Quantification of Radiomics features of Peritumoral Vasogenic Edema extracted from fluid-attenuated inversion recovery images in glioblastoma and isolated brain metastasis, using T1-dynamic contrast-enhanced Perfusion analysis.
Parvaze PS; Bhattacharjee R; Verma YK; Singh RK; Yadav V; Singh A; Khanna G; Ahlawat S; Trivedi R; Patir R; Vaishya S; Shah TJ; Gupta RK
NMR Biomed; 2023 May; 36(5):e4884. PubMed ID: 36453877
[TBL] [Abstract][Full Text] [Related]
38. IDH1 mutation prediction using MR-based radiomics in glioblastoma: comparison between manual and fully automated deep learning-based approach of tumor segmentation.
Choi Y; Nam Y; Lee YS; Kim J; Ahn KJ; Jang J; Shin NY; Kim BS; Jeon SS
Eur J Radiol; 2020 Jul; 128():109031. PubMed ID: 32417712
[TBL] [Abstract][Full Text] [Related]
39. Differentiation Between True Tumor Progression of Glioblastoma and Pseudoprogression Using Diffusion-Weighted Imaging and Perfusion-Weighted Imaging: Systematic Review and Meta-analysis.
Tsakiris C; Siempis T; Alexiou GA; Zikou A; Sioka C; Voulgaris S; Argyropoulou MI
World Neurosurg; 2020 Dec; 144():e100-e109. PubMed ID: 32777397
[TBL] [Abstract][Full Text] [Related]
40. Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma.
Ingrisch M; Schneider MJ; Nörenberg D; Negrao de Figueiredo G; Maier-Hein K; Suchorska B; Schüller U; Albert N; Brückmann H; Reiser M; Tonn JC; Ertl-Wagner B
Invest Radiol; 2017 Jun; 52(6):360-366. PubMed ID: 28079702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
